Kollipara, VenkateswaraHorowitz, MitchellLantz, JefferyNagy-Agren, Stephanie E.2022-09-302022-09-302022-03-122212-5531IntJMycobacteriol_2022_11_1_120_339504 (PII)http://hdl.handle.net/10919/112040Mycobacterium kansasii is the second most common cause of nontuberculous mycobacterial (NTM) lung disease after Mycobacterium avium complex infection in the United States. [1] The first-line therapy for M. kansasii is a three-drug regimen including rifampin, isoniazid, and ethambutol. We present a case of a patient with pulmonary M. kansasii who developed bullous skin lesions while receiving this regimen and again after rechallenge with ethambutol. In patients with intolerance to one of the first-line antibiotics, a multidisciplinary team approach to starting second-line agents is needed. Ethambutol should be included in the differential diagnosis of drug-induced bullous skin lesions in treated patients with NTM, who develop new onset rash with blisters or ulceration.Pages 120-122application/pdfenCreative Commons Attribution-NonCommercial-ShareAlike 4.0 InternationalDirect immunofluorescentMycobacterium kansasiidrug-induced skin reactionsethambutolpemphigus vulgarissuprabasilar bullous skin lesionOrphan DrugRare DiseasesTuberculosisLung2 Aetiology2.1 Biological and endogenous factorsInfectionLungHumansMycobacterium kansasiiMycobacterium avium-intracellulare InfectionEthambutolIsoniazidMycobacterium Infections, NontuberculousArticle - Refereed2022-09-30https://doi.org/10.4103/ijmy.ijmy_204_21111Nagy-Agren, Stephanie [0000-0003-2481-196X]352950352212-554X